Charles River Laboratories reported $221.85M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Agilent USD 444M 45M Jun/2026
Align Technology USD 193.04M 1.72M Sep/2026
Bio-Rad Laboratories USD 72.6M 750.1M Jun/2026
Bruker USD 83.5M 13.9M Sep/2026
Cardinal Health USD 819M 5M Sep/2026
Charles River Laboratories USD 221.85M 101.96M Sep/2026
Cigna USD 2.4B 217M Sep/2026
Concord Medical Services Hldg CNY -94.68M 49.97M Dec/2025
CVS Health USD 3.57B 3.16B Sep/2026
Danaher USD 1.25B 118M Sep/2026
Dentsply International USD 38M 46M Sep/2026
Elevance Health USD 2.15B 149M Sep/2026
Humana USD 1.36B 394M Jun/2026
Illumina USD 305M 45M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Intrexon USD -26.3M 2.91M Jun/2024
IQVIA Holdings USD 608M 1.99B Sep/2026
Laboratory Of America USD 418M 38.7M Sep/2026
Lakefront Biotherapeutics EUR -41.17M 2.34M Sep/2026
Lonza CHF 673M 54M Jun/2025
McKesson USD 1.69B 266M Sep/2026
Merck EUR 660M 437M Sep/2026
Mettler Toledo International USD 300.2M 12.65M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Quest Diagnostics USD 479M 20M Sep/2026
Revvity USD 124.63M 1.51M Sep/2026
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
UnitedHealth USD 6.34B 1.65B Sep/2026
Veradigm USD -45.47M 70.47M Dec/2022
Waters USD 10M 138M Jun/2026
West Pharmaceutical Services USD -199.7M 378.8M Sep/2026